Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bpax @. 44 . Ais @ 1.80, wow. Glad I was out of Ais
ymi thanks, should move much higher in near future
ymi- agree, great plan.
YMI(1.70, up 16.44 %)- 7.6 Million shares traded . feel really good about holding em,
Great info sheff , thanks.
Great , thanks.
NGSX- Man! for now i am staying away. will see what comes out of this cave.
NGSX-Was planning to start a position in ngsx, does anybody knows whats the deal with it right now!!!!!!!
YMI- FWIW Roadman and renshaw, the big pumper gave YMi $ 6 target price today and also wells fargo recommends buying on the strength.
YMI- 1.68 I have not sold yet. i dont think valuation are reasonable here. i understand risk of dilution but it was trading at 1.87 pre data release one month before. it has great results, great prospect for partnership , there is no reason it should trade at these levels, good luck.
Thank you for your advise sheff, I will make sure my profit are not paper profit only . Thanks for the heads up about YMI , it came from no where when you posted it first on this board, good stuff.
Thank you sir, great analysis
Will look forward to it
Thank you sir
that is sage advise and i will do that . Thanks
thanks, ram. you know it was painful to hold through . i did not know about this company at all a, month ago. Sheff gave the heads up and when i digged deep into it , i liked what i saw. hope fully it will pay off.
quarter million shares already traded, up 24% @ 1.81.
YMI- good article from AF:
Highly anticipated results from a mid-stage and multi-center study of YM Bio's myelofibrosis drug CYT387 were released Monday night showing the ballyhooed (and controversial) anemia response appears to be real.
Of the 68 myelofibrosis patients who were transfusion dependent when the study started, 46% became transfusion independent for a minimum of 12 weeks and maintained hemoglobin levels equal to or above 8 g/dl.
Of the 26 transfusion-dependent patients treated with the 300 mg dose of '387, 62% became transfusion independent and maintained hemoglobin levels equal to or above 8 g/dl.
These '387 anemia response data are stronger and more credible than what was presented last spring because Monday's results are culled from many more patients enrolled at multiple clinical trial sites.
If '387 can reverse the anemia associated with myelofibrosis, it will have a legitimate superiority claim over Incyte's(INCY_) recently approved myelofibrosis drug Jakafi, which has no effect on anemia.
Based on the positive anemia response data released Monday, the current valuation gap between Incyte ($1.8 billion market cap) and YM Bio ($170 million market cap) is way too big even considering '387 is two or three years behind in clinical development.
YM Bio shares closed Monday at $1.46 but were up 24% to $1.81 in after-hours trading as the '387 data were released at the American Society of Hematology (ASH) annual meeting.
--Written by Adam Feuerstein in Boston.
remember they have a webcast at 6 30 PT or 830 CST. dont miss it.
honestly, dont know will decide how it trades.
NOPE!!!!!!!!!!!
GOOd luck buddy, YMI @1.79
YMI- CYT387 Ph1/2 study Updated Results; Anemia results: 65% are transfusion independent for min 12wks
BOO yah to ya!!!!!!
YMI_ 1.90(UP 30%) after hours.
YMI
Anemia Response
Of the 68 patients who were transfusion dependent at baseline, to date 54% have become transfusion independent for a minimum of 12 weeks. The median duration of the transfusion-free period has not yet been reached (range: 82-506 days, ongoing). More than 25% of subjects who were not receiving transfusions while on study experienced at least a 1 g/dL increase in hemoglobin lasting for more than eight weeks.
Of the 26 patients who were dosed at 300mg QD and were transfusion dependent at baseline, to date 65% have become transfusion independent for a minimum of 12 weeks
CYT387 is well tolerated in myelofibrosis patients for dosing periods up to and exceeding two years. Reported adverse effects include thrombocytopenia; transient, mild dizziness; mild peripheral neuropathy; and abnormalities in liver/pancreas-related laboratory tests. Treatment emergent anemia and neutropenia were rarely reported.
YMI: ADDED 9900 shares of ymi here.
tried to got it filled at 1.42 and 1.45, did not got filled for 2 hours, Finally got filled at 1.46.
AIS: you are right, very steady.
YONG, good trade, RTN
if you believe that data should be good , buy it. if you believe data will be bad sell it, as simple as that. i am holding i think data will be good, i dont care about short term price, it will catch up eventually.
Thanks for the up date
Exactly, that,s what i think. and i also think it will run hard on monday.
Ymi- 1.68( up 6%) , 550 K shares already traded.
YMI- 1.65 flirting with your 50 DMA.
ALXA_ i did not have any position in to ALXA this time fortunately. FDA is very very stringent about any drug going directly into the lungs and especially if that drug is not used for respiratory illness. drug makers will do what they want to do but i am with FDA on this lung issue. LUNG alveoli are so delicate that there is every reason to be very cautious. people develope lung fibrosis decades after exposing themselves to asbestos etc.
I will be very cautious with any new drug going in to the lungs. For example DSCO, going to the FDA for the fifth time for a respiratory ailment (RDS) , just to give you a perspective.
AIS: Ron, why are you so confident that , libigel data would be positive